Stanford researchers and collaborators introduce Germinal, a generative pipeline that designs antibodies for a chosen protein epitope by co-optimizing AlphaFold-Multimer structure scores with an antibody language model. In Nature Biotechnology, they report testing only 43 to 101 designs per antigen across four targets, including PD-L1 and a viral protein, with hit rates of roughly 4% to 22% and some nanobodies reaching nanomolar affinities after mammalian expression. The claim is de novo binders without huge library screens, a faster path to molecular tools and drug leads. Caveat: wet-lab filtering remains essential, and a binding hit is not yet a developable therapeutic.